Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

NCT02723838 is registered in ClinicalTrials.gov with Oncolytics Biotech as lead sponsor.

NCT NCT02723838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02723838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder
Lead sponsor
Oncolytics Biotech
Phase
Phase 1
Overall status
Withdrawn
Start date
February 28, 2017
Completion date
February 28, 2018
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

muscle-invasive transitional cell carcinoma of the bladder